导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -7.17% | 3587/4773 |
| 近一周 | -2.86% | 4332/5465 |
| 近一月 | -2.42% | 1653/5421 |
| 近一季 | -9.78% | 3638/5231 |
| 近半年 | -15.77% | 4112/4920 |
| 近一年 | -7.85% | 3283/4394 |
| 近两年 | 44.70% | 1685/2954 |
| 近三年 | 8.19% | 1792/2253 |
| 成立以来 | -45.60% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.12% 1053/4961 |
-3.84% 3478/5312 |
- - |
- - |
| 2025 | 17.84% 2349/4813 |
3.24% 1144/3635 |
3.07% 1177/4076 |
12.08% 3101/4524 |
-1.20% 2865/4813 |
| 2024 | 6.33% 1771/3463 |
-5.35% 1878/2808 |
-11.15% 2509/3014 |
18.12% 1055/3129 |
7.05% 463/3463 |
| 2023 | -11.24% 1382/2656 |
3.47% 1185/2280 |
-2.78% 665/2385 |
-6.22% 1459/2515 |
-5.91% 1554/2655 |
| 2022 | -25.69% 1339/2207 |
-13.57% 787/1919 |
-2.97% 1793/2016 |
-9.45% 280/2113 |
-2.15% 1777/2208 |
| 2021 | 19.96% 187/1822 |
7.54% 70/1255 |
-6.06% 1279/1330 |
13.87% 85/1466 |
4.28% 343/1822 |
| 2020 | -3.73% 961/1250 |
-4.31% 355/1028 |
2.87% 958/1067 |
5.58% 907/1164 |
-7.36% 1157/1184 |
| 2019 | 3.03% 803/1092 |
22.22% 574/754 |
-6.61% 514/804 |
-10.09% 837/850 |
0.39% 884/918 |
| 2018 | -45.48% 622/834 |
- - |
- - |
- - |
-9.17% 132/691 |
| 2017 | -7.16% 519/714 |
- - |
- - |
- - |
- - |
| 2016 | -14.21% 334/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 交银中证环境治理(LOF)A VS. 长安沪深300非周期A(740101) |